These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 37357833)

  • 1. Models of the putative antimony(V)-diolate motifs in antileishmanial pentavalent antimonial drugs.
    Lindquist-Kleissler B; Johnstone TC
    Dalton Trans; 2023 Jul; 52(27):9229-9237. PubMed ID: 37357833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
    Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
    Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoscaled hydrated antimony (V) oxide as a new approach to first-line antileishmanial drugs.
    Franco AM; Grafova I; Soares FV; Gentile G; Wyrepkowski CD; Bolson MA; Sargentini É; Carfagna C; Leskelä M; Grafov A
    Int J Nanomedicine; 2016; 11():6771-6780. PubMed ID: 28008252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
    Roberts WL; Berman JD; Rainey PM
    Antimicrob Agents Chemother; 1995 Jun; 39(6):1234-9. PubMed ID: 7574507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentavalent antimonials: new perspectives for old drugs.
    Frézard F; Demicheli C; Ribeiro RR
    Molecules; 2009 Jun; 14(7):2317-36. PubMed ID: 19633606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sb(V) Kaempferol and Quercetin Derivative Complexes: Synthesis, Characterization and Antileishmanial Activities.
    Abdeyazdan S; Mohajeri M; Saberi S; Mirzaei M; Ayatollahi SA; Saghaei L; Ghanadian M
    Iran J Pharm Res; 2022 Dec; 21(1):e128379. PubMed ID: 36942069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpectedly high levels of antimony (III) in the pentavalent antimonial drug Glucantime: insights from a new voltammetric approach.
    Salaün P; Frézard F
    Anal Bioanal Chem; 2013 Jun; 405(15):5201-14. PubMed ID: 23612869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimony oxidation states in antileishmanial drugs.
    Franco MA; Barbosa AC; Rath S; Dorea JG
    Am J Trop Med Hyg; 1995 May; 52(5):435-7. PubMed ID: 7771610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimony(V) complex formation with adenine nucleosides in aqueous solution.
    Demicheli C; Frézard F; Lecouvey M; Garnier-Suillerot A
    Biochim Biophys Acta; 2002 Apr; 1570(3):192-8. PubMed ID: 12020809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.
    Borborema SE; Osso Junior JA; Andrade Junior HF; Nascimento Nd
    Rev Soc Bras Med Trop; 2016 Apr; 49(2):196-203. PubMed ID: 27192589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimonate and sodium stibogluconate.
    Frézard F; Martins PS; Barbosa MC; Pimenta AM; Ferreira WA; de Melo JE; Mangrum JB; Demicheli C
    J Inorg Biochem; 2008 Apr; 102(4):656-65. PubMed ID: 18061680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance in Indian visceral leishmaniasis.
    Sundar S
    Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.
    Fernández OL; Diaz-Toro Y; Ovalle C; Valderrama L; Muvdi S; Rodríguez I; Gomez MA; Saravia NG
    PLoS Negl Trop Dis; 2014 May; 8(5):e2871. PubMed ID: 24853871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antileishmanial, DNA Interaction, and Docking Studies of Some Ferrocene-Based Heteroleptic Pentavalent Antimonials.
    Rauf MK; Shaheen U; Asghar F; Badshah A; Nadhman A; Azam S; Ali MI; Shahnaz G; Yasinzai M
    Arch Pharm (Weinheim); 2016 Jan; 349(1):50-62. PubMed ID: 26627058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatotoxicity of pentavalent antimonial drug: possible role of residual Sb(III) and protective effect of ascorbic acid.
    Kato KC; Morais-Teixeira E; Reis PG; Silva-Barcellos NM; Salaün P; Campos PP; Dias Corrêa-Junior J; Rabello A; Demicheli C; Frézard F
    Antimicrob Agents Chemother; 2014; 58(1):481-8. PubMed ID: 24189251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of pentavalent antimony by trypanothione and formation of a binary and ternary complex of antimony(III) and trypanothione.
    Yan S; Li F; Ding K; Sun H
    J Biol Inorg Chem; 2003 Jul; 8(6):689-97. PubMed ID: 12827457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural, spectroscopic and computational examination of the dative interaction in constrained phosphine-stibines and phosphine-stiboranes.
    Chalmers BA; Bühl M; Athukorala Arachchige KS; Slawin AM; Kilian P
    Chemistry; 2015 May; 21(20):7520-31. PubMed ID: 25820876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible links between sickle cell crisis and pentavalent antimony.
    Garcerant D; Rubiano L; Blanco V; Martinez J; Baker NC; Craft N
    Am J Trop Med Hyg; 2012 Jun; 86(6):1057-61. PubMed ID: 22665619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential toxicity of antimonial compounds and their effects on glutathione homeostasis in a human leukaemia monocyte cell line.
    Wyllie S; Fairlamb AH
    Biochem Pharmacol; 2006 Jan; 71(3):257-67. PubMed ID: 16318845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New delivery strategies for the old pentavalent antimonial drugs.
    Frézard F; Demicheli C
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1343-58. PubMed ID: 21029028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.